This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Investigators from multiple Japanese institutions conducted a retrospective observational study to assess the long-term clinical course among children with frequently relapsing nephrotic syndrome (FRNS) and steroid-dependent nephrotic syndrome (SDNS) treated after treatment with rituximab. Patients with childhood-onset FRNS or SDNS, who had received 375 mg/m2 rituximab once weekly for 4 weeks as part of a clinical trial conducted from 2008–2010, were eligible to participate. FRNS was defined as ≥4 relapses of nephrotic syndrome within any 12-month period. SDNS was defined as 2 consecutive relapses during tapering or within 2 …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
In this issue
Related Articles
Cited By...
- No citing articles found.